English summaries of Pegpesen® (inpegsomatropin injection) organized by topic: name and composition, dosing, adverse events, precautions, contraindications, pharmacology, nonclinical data, and links to trial outcomes.
Current official dossier
Primary product sources
Consult Amoytop's current product center, NMPA approval announcement, ClinicalTrials.gov registration, and PubMed-indexed publications alongside the topic summaries below.
Section map
Name, ingredients & strengths
INN, trade name, molecular attributes, excipients, presentation forms.
Open →Dosage, missed doses & injection
Weekly dose, sites, cartridge + TopPen I pathway vs vial/syringe.
Open →Adverse events & immunogenicity
Phase II/III safety database, MedDRA summary, ADA rates vs comparator.
Open →Precautions
Full precaution topics in expandable sections for easier scanning.
Open →Contraindications
Hypersensitivity, closed epiphyses, malignancy, acute critical illness.
Open →Clinical pharmacology
Mechanism reference, pharmacodynamics, PK, interactions, overdosage.
Open →Pharmacology & toxicology
Pharmacologic effect narrative, genotoxicity, reproductive toxicity.
Open →Clinical trials (efficacy)
Registrational study design, endpoints, and outcome tables.
Open →